Johnson & Johnson’s Post

Exciting News in Neuroscience! Another significant milestone for the neuroscience industry as Intra-Cellular Therapies has been acquired by Johnson & Johnson. This marks yet another major acquisition by big pharma, further highlighting the growing focus and investment in this space. Who do you think might be next? #Neuroscience #Pharma #Acquisition #Innovation

Exciting to see this acquisition of Intra-Cellular Therapies by Johnson & Johnson Innovative Medicine Johnson & Johnson. Looking at objectively, Johnson & Johnson excels in scale, stability, and diversification but faces legal and adaptability issues. Intra-Cellular Therapies is innovative and focused but vulnerable due to its narrow product scope and smaller size. Both companies have unique strengths suited to their strategic goals. I'm sure they will put the best eggs together and be successful, providing vital assistance to those that are in dire need for them. I'm excited to see how this works out in long term.

Exciting to see this acquisition of Intra-Cellular Therapies by Johnson & Johnson Innovative Medicine Johnson & Johnson. Looking at objectively, Johnson & Johnson excels in scale, stability, and diversification but faces legal and adaptability issues. Intra-Cellular Therapies is innovative and focused but vulnerable due to its narrow product scope and smaller size. Both companies have unique strengths suited to their strategic goals. I'm sure they will put the best eggs together and be successful, providing vital assistance to those that are in dire need for them. I'm excited to see how this works out in long term. #medicine #therapy #pharma #johnsonandjohnson #clinicaltrials #clinicalresearch #health #medicalresearch

🌟 Exciting News from the Healthcare Conference in San Francisco! 🌟 Johnson & Johnson has announced its acquisition of Intra-Cellular, one of BB Biotech's core holdings. This is a major boost for the biotech sector at the start of the year and has propelled BB Biotech's NAV to climb above 45. Stay tuned—more exciting updates from San Francisco are on the way! 🚀 #BBBiotech #Innovation #Healthcare #Biotech

Every week should start like this….. 11+years ago we were approached and engaged to assist in the ultimately successful $60m PIPE and go public transaction for an early stage neurosciences company called Intra Cellular at $3.17 a share at a sub $100m post money valuation . With (then) two promising early clinical stage assets, today Intra-Celluar Therapies has transformed into a powerhouse. It has the first and only approved treatment for bipolar 1 and 2 in Caplyta, is approved for the treatment of schizophrenia in adults and has a robust and promising clinical stage pipeline of potential best in class assets related to generalized anxiety disorder and Alzheimer’s disease related psychosis and agitation. Fast forward to today, J&J has acquired the company for $14.6 billion at $132 a share, bringing a long and successful, albeit rocky, road as a stand alone company to an end. We celebrate the news, the company’s entire management group and employees, and most importantly, all the team and investors who 11+ years ago diligenced, assisted and facilitated that initial financing and bet on the science, ultimately proving again small teams and platforms can compete effectively and efficiently while creating powerful long term and impactful drugs AND returns.

#News: InMed Pharmaceuticals Announces INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer’s Disease Study Read full news release: https://ow.ly/W3fl50UJU2m $INM #Alzheimers #Neuroinflammation #Preclinical #study

The global market for multiple sclerosis drugs anticipated to reach $35.7 billion by 2031, steadily growing at a of CAGR 6.5% over forecast period, driven by large number of both existing therapeutics, and new entrants in the marketplace. https://lnkd.in/eR9J7SA

Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dilated Cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Dilated Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

The global market for multiple sclerosis drugs anticipated to reach $35.7 billion by 2031, steadily growing at a of CAGR 6.5% over forecast period, driven by large number of both existing therapeutics, and new entrants in the marketplace. https://lnkd.in/e-2Ng2q